Method of monitoring treatment
AssigneeLDN Pharma Limited
InventorWai Liu
Life of this patent
Estimating the term…
Abstract
The invention relates to a method for monitoring the treatment of a subject undergoing therapy with an active that is naltrexone or a metabolite or analogue thereof, comprising: measuring the gene expression profile of any of the genes listed in Table 1 or Table 2, in a sample of CD3+ cells obtained from the subject undergoing treatment; wherein if the expression of any of the genes in Table 1 is increased compared to a control, or if any of the genes listed in Table 2 is decreased compared to a control the active is being administered at an effective level.
Claims20
A method for monitoring the treatment of a subject undergoing therapy with an active that is naltrexone or a metabolite or analogue thereof, comprising:
- measuring the gene expression profile of any of the genes listed in a):
- a) i. S100 calcium binding protein A6, mRNA;
- ii. RAS protein activator like 3, mRNA;
- iii. Mitogen-activated protein kinase kinase kinase kinase 1, mRNA;
- iv. Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase, mRNA;
- v. DR1-associated protein 1 (negative cofactor alpha 2), mRNA;
- vi. Castor zinc finger 1, transcript variant 2, mRNA;
- vii. Aldehyde dehydrogenase 4 family, member A1, mRNA;
- viii. Phenylalanine hydroxylase, mRNA;
- ix. Myosin, light polypeptide kinase, transcript variant 5, mRNA;
- x. Eukaryotic translation initiation factor 4B, mRNA;
- xi. Olfactory receptor, family 10, subfamily A, member 6, mRNA;
- xii. Ezrin, transcript variant 1, mRNA;
- xiii. Actin, beta, mRNA;
- xiv. PRP8 pre-mRNA processing factor 8 homolog (S. cerevisiae), mRNA;
- xv. Integrin, beta 2 (complement component 3 receptor 3 and 4), mRNA;
- xvi. Hippocalcin-like 1, transcript variant 2, mRNA;
- xvii. Sparc/osteonectin, cwcv and kazal-like domains proteoglycan 2, mRNA;
- xviii. Poliovirus receptor-related 2 (herpesvirus entry mediator B), mRNA;
- xix. Nucelobindin 1, mRNA;
- or b):
- b) i. WD repeat domain 75, mRNA;
- ii. Baculoviral IAP repeat-containing 3, transcript variant, mRNA;
- iii. CDKN2A interacting protein, mRNA;
- iv. Dynein, light chain, LC8-type 2, mRNA;
- v. Eukaryotic translation initiation factor 2, subunit 3 gamma, mRNA;
- vi. ArfGAP with SH3 domain, Ankyrin repeat and PH domain 1, mRNA;
- vii. Potassium channel tetramerisation domain containing 6, mRNA;
- viii. Proteasome (prosome, macropain) activator subunit 2, mRNA;
- ix. Mortality factor 4 like 1, transcript variant 2, mRNA;
- x. Metal-regulatory transcription factor 1, mRNA;
- xi. Peroxisomal D3,D2-enoyl-CoA isomerase, transcript, mRNA;
- xii. Programmed cell death 4 (neoplastic transformation inhibitor), mRNA;
- xiii. Histone cluster 1, H4c, mRNA;
- xiv. BCL2-associated transcription factor 1, transcript variant, mRNA;
- xv. Eukaryotic translation initiation factor 3, subunit E, mRNA;
- xvi. LSM5 homolog, U6 small nuclear RNA associated (S. cerevisiae), mRNA;
- xvii. H3 histone, family 3A, mRNA;
- xviii. Eukaryotic translation initiation factor 3, subunit M, mRNA;
- xix. CDC42 small effector 2, transcript variant 2, mRNA;
- in a sample of CD3+ cells obtained from the subject undergoing treatment;
- wherein if the expression of any of the genes in a) is increased compared to a control, or if any of the genes listed in b) is decreased compared to a control the active is being administered at an effective level.
Dependencies are inferred from the claim text.